Literature DB >> 8691436

Chemical synthesis of benzamide adenine dinucleotide: inhibition of inosine monophosphate dehydrogenase (types I and II).

A Zatorski1, K A Watanabe, S F Carr, B M Goldstein, K W Pankiewicz.   

Abstract

Treatment of 3-(2,3-O-isopropylidene-beta-D-ribofuranosyl)benzamide (6) with POCl3 in (EtO)3-PO afforded only little phosphorylation product (8, 5%), but the major product was 5'-chlorobenzamide riboside (7, 85%). Reaction of 6 with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite followed by 2-cyanoethanol/tetrazole treatment and oxidation with tert-butyl peroxide gave a 1:1 mixture of the desired 5'-O-bis(2-cyanoethyl) phosphate 9 and the chloro derivative 7. This mixture was treated with methanolic ammonia and partitioned between CHCl3 and water. The 2',3'-O-isopropylidenebenzamide mononucleotide (8) was obtained in 21.2% overall yield from the aqueous layer. Compound 8 was then converted into the corresponding imidazolide 11b which, upon coupling with 2',3'-O-acetonide of AMP, afforded the acetonide of benzamide adenine dinucleotide (15) in 94% yield together with small amounts of symmetrical pyrophosphates P1,P2-bis(2',3'-O-isopropylideneadenosin-5'-yl)pyrophosphate (13, 3%) and P1,P2-bis(2',3'-O-isopropylidene-3-(carbamoylphenyl)-5'-ribosyl)py rophosphate (14, 2%). Deprotection of 15 with Dowex 50/H+ in water afforded the desired benzamide adenine dinucleotide (BAD) in 93% yield. BAD inhibits inosine monophosphate dehydrogenase type I (IC50 = 0.78 microM) and type II (IC50 = 0.88 microM) with same degree of potency.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691436     DOI: 10.1021/jm9601415

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Chemoenzymatic Preparation of 4'-Thioribose NAD.

Authors:  Xiao-Nan Zhang; Zhefu Dai; Qinqin Cheng; Yong Zhang
Journal:  Curr Protoc Nucleic Acid Chem       Date:  2019-04-05

2.  Structure-activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors.

Authors:  Sammy R Shaver; Janet L Rideout; William Pendergast; James G Douglass; Edward G Brown; José L Boyer; Roshni I Patel; Catherine C Redick; Arthur C Jones; Maryse Picher; Benjamin R Yerxa
Journal:  Purinergic Signal       Date:  2005-03-07       Impact factor: 3.765

3.  NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains.

Authors:  Marie-France Langelier; Levani Zandarashvili; Pedro M Aguiar; Ben E Black; John M Pascal
Journal:  Nat Commun       Date:  2018-02-27       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.